Abstract: Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.
Abstract: The current disclosure provides a process for enzymatically converting a saccharide into allulose. The invention also relates to a process for preparing allulose where the process involves converting fructose 6-phosphate (F6P) to allulose 6-phosphate (A6P), catalyzed by allulose 6-phosphate 3-epimerase (A6PE), and converting the A6P to allulose, catalyzed by allulose 6-phosphate phosphatase (A6PP).
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
July 7, 2020
Assignee:
BONUMOSE LLC
Inventors:
Daniel Joseph Wichelecki, Edwin O. Rogers
Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
June 23, 2020
Assignee:
Purdue Research Foundation
Inventors:
Alyssa Panitch, John Eric Paderi, Kinam Park, Katherine Allison Stuart, Steve Higbee
Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.
Type:
Grant
Filed:
September 23, 2013
Date of Patent:
May 5, 2020
Assignee:
Novozymes A/S
Inventors:
Steen Troels Jorgensen, Poul Erik Pedersen
Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RT and polymerase inhibitors relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
Type:
Grant
Filed:
March 17, 2017
Date of Patent:
March 24, 2020
Assignee:
Roche Molecular Systems, Inc.
Inventors:
Keith Bauer, Thomas W. Myers, Fred Reichert, Joseph San Filippo, Rachel Shahinian, Shawn Suko
Abstract: Modified Protein A, Protein G, Protein L, or Protein A/G that lacks antibody binding activity, and methods of the modified protein's use for purifying antibodies is provided.
Abstract: The present invention is directed to methods and compositions for typing of Lactobacillus buchneri bacterial strains, detecting the presence of a L. buchneri in a sample, identifying a strain of L. buchneri having resistance to an invasive foreign genetic element, modifying the resistance of bacteria and archeae to an invasive foreign genetic element, and introducing nicks into or cleaving double stranded DNA for genome editing.
Type:
Grant
Filed:
October 29, 2014
Date of Patent:
March 10, 2020
Assignee:
NORTH CAROLINA STATE UNIVERSITY
Inventors:
Rodolphe Barrangou, Alexandra E. Briner
Abstract: A dissolved CO2 change in aqueous solutions affects directly the intracellular pH (pHi) value as it does so by influencing therefore important cellular processes. The enzyme carbonic anhydrase II (CAII) catalyzes the equilibrium of CO2 in aqueous solutions and because it alters the speed at which this equilibrium is reached it was identified as a strong candidate for metabolic engineering. The cell line stably expressing hCAII presented a better initial re-alkalinization of cytoplasm after induced CO2 acid load. The most alkaline pHi value associated to the lowest pHi variations was observed for that cell line in long term increased CO2 levels. In general, the increased CO2 profile triggered the quicker progress of G0G1-cell cycle phase for both transfected and control cell lines.
Type:
Grant
Filed:
November 13, 2014
Date of Patent:
December 24, 2019
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Betina Da Silva Ribeiro, Markus Emmler, Alexander Jockwer
Abstract: Provided herein are oral care compositions comprising antifreeze proteins (AFPs) useful in methods of repairing or inhibiting dental erosion, promoting dental remineralization, and/or enhancing the anti-cavity effects of fluoride.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
December 17, 2019
Assignee:
BASF SE
Inventors:
Nina Schneider, Thomas Subkowski, Stefan Jenewein, Marvin Karos, Claus Bollschweiler, Volker Wendel, Jianhong Qiu, LaTonya Kilpatrick-Liverman, Lynette Zaidel
Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
December 3, 2019
Assignee:
EDITAS MEDICINE, INC.
Inventors:
Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
November 12, 2019
Assignee:
TEEWINOT TECHNOLOGIES LIMITED
Inventors:
Richard Peet, Malcolm J. Kavarana, Robert Winnicki, Marc Donsky, Mingyang Sun
Abstract: A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.
Type:
Grant
Filed:
March 9, 2018
Date of Patent:
October 1, 2019
Assignee:
Healthgen Biotechnology Co., Ltd.
Inventors:
Daichang Yang, Yang He, Guangfei Li, Jingru Liu
Abstract: The invention provides tissue repair compositions and methods of making the tissue repair compositions. Also featured are methods of treatment using the tissue repair compositions and articles of manufacture that include the tissue repair compositions.
Abstract: The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.
Type:
Grant
Filed:
April 28, 2015
Date of Patent:
July 30, 2019
Assignee:
GELITA AG
Inventors:
Steffen Oesser, Monika Giesen-Wiese, Hans-Ulrich Frech, Stephan Hausmanns
Abstract: A film of the present invention contains a polypeptide derived from spider silk proteins. The decomposition temperature of the film is 240 to 260° C. The film absorbs ultraviolet light having a wavelength of 200 to 300 nm and has a light transmittance of 85% or more at a wavelength of 400 to 780 nm. The film is transparent and colorless in a visible light region. A method for producing a film of the present invention includes: dissolving a polypeptide derived from spider silk proteins in a dimethyl sulfoxide solvent to prepare a dope; and cast-molding the dope on a surface of a base. Thus, the present invention provides a spider silk protein film that can be formed easily and has favorable stretchability, and a method for producing the same.
Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonization and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.
Type:
Grant
Filed:
January 20, 2016
Date of Patent:
May 28, 2019
Assignee:
HYPHARM GMBH
Inventors:
Anna Scherzinger, Sonja Molinaro, Bernd Buchberger
Abstract: An object of the present invention is to modify a wild-type enzyme that is less reactive in the presence of an organic solvent to provide altered carbonyl reductases having better reactivity in the presence of the organic solvent than the wild-type enzyme, and/or to provide transformants producing such reductases. The present inventors have found altered carbonyl reductases having better reactivity in the presence of an organic solvent than the wild-type enzyme, from among a mutant enzyme library prepared by randomly mutating the wild-type enzyme gene, thereby arriving at completion of the present invention.